oleander clinical trial

[Guest guest]

Thank you, Tony, for forwarding this message.

Very helpful.

Crandell mentioned a published peer-reviewed article by Dr.Newman andothers of cardiac glycosides and the science relative to their use intumor therapy.

Would you please ask him where to find a copy of this article online?

Thank you very much!

Angel

 

A message from the CEO of oleander medicine maker Phoenix Biotech

Posted by: "Tony"

Thu Apr 10, 2008 12:44 pm (PDT)

In response to one of our members pleas for further proof a messagewas forwarded to Crandell Addington, CEOt of Phoenix Biotech. Here ishis reply:Good morning, all:We have an agent in Phase I Clinical Trials at M.D.Anderson Phase IClinic currently. You can look it up on www.clinicaltrials.gov byusing PBI-05204 as the agent. "PBI" identifying Phoenix Biotechnology,Inc. You can see the details there. It is administered in capsularform, not as a "pill" such as you might associate with the common formof aspirin.This agent is a supercritical extract of Nerium Oleander for which wehave received a Notice of Allowance from the USPTO. The principalcardiac glycoside of this extract is oleandrin, although it doescontain other molecules that suggest in vitro that they aresynergistic with the oleandrin.The year 2000 Phase I Clinical Trial of Anvirzel (published) does notethree patients with disease stabilization. This Trial was suspendedwhen the bolus became to voluminous for the intramuscular route ofadministration to continue. As I recall, it did not approach itsprotocol for MTD (maximum tolerated dose without serious adverseadvents) that is the primary endpoint of all Phase I Clinical Trials.(Joe Nester of Nerium Biotechnology can give you more details.) So,the disease stabilization suggests that increased dose levels mighthave had an even more therapeutic result.I have a friend who was diagnosed with terminal gastronoma almost sixyears ago. He used Anivrzel as adjuvant therapy while receiving theconventional "cocktail" at the pancreatic clinic at M.D.AndersonCancer Center. He continues to self-administer Anvirzel to this day,and has not received any conventional chemotherapy in years. Hedoesn't mind talking about it. Let me know if you want to talk with him.There is a recent published peer-reviewed article by Dr.Newman andothers of cardiac glycosides and the science relative to their use intumor therapy.Hope this helps.Have a nice day.Crandell AddingtonCEO Phoenix Biotechnology, Inc.